Showing results (501-510 of 604) with videos related to
Sort By:
Pageof 61
Annals of Neurology|March 27, 2021
Amylin Analog Pramlintide Induces Migraine-like Attacks in PatientsHashmat Ghanizada, Mohammad Al-Mahdi Al-Karagholi, Christopher S Walker, et al.Science (New York, N.Y.)|February 22, 2003
Late Pliocene Homo and hominid land use from Western Olduvai Gorge, TanzaniaRobert J Blumenschine, Charles R Peters, Fidelis T Masao, et al.The Journal of Biological Chemistry|March 26, 2016
Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular PropertiesHarriet A Watkins, Madhuri Chakravarthy, Rekhati S Abhayawardana, et al.JAMA Dermatology|November 9, 2017
Interdisciplinary Perspectives on Sun SafetyAlan C Geller, Nina G Jablonski, Sherry L Pagoto, et al.CPT: Pharmacometrics & Systems Pharmacology|June 28, 2017
Commentary on the MID3 Good Practices PaperEfthymios Manolis, Jacob Brogren, Susan Cole, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectoryElyse Shuk, Alexander N Shoushtari, Jason Luke, et al.BMJ Open|November 5, 2017
Protocol for the HAPPY Hearts study: cardiovascular screening for the early detection of future adverse cardiovascular outcomes in middle-aged and older women: a prospective, observational cohort studyKevin F Boreskie, D Scott Kehler, Eduardo C Costa, et al.Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.NPJ Vaccines|April 2, 2026
Cattle antibodies identify a cross-serotype broadly neutralising foot-and-mouth disease virus epitopeMarie Bonnet-Di Placido, Helen M E Duyvesteyn, Angela W Steyn, et al.Cancer|October 4, 2018
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trialsJoanne M Jeter, Tawnya L Bowles, Clara Curiel-Lewandrowski, et al.Pageof 61